Actelion has a dedicated team focused on identifying innovation from external sources that complements our business approach. Once identified, Actelion is rapid, proactive and open in creating benefits for both parties. We commit ourselves to the project we share with our partner, to make the product a global success.
Actelion / ReveraGen BioPharma, Inc. collaboration

Actelion signed a license, collaborative development and commercialization agreement with ReveraGen BioPharma, Inc., a corporation organized under the laws of Delaware, US, to research and co-develop vamorolone, a non-hormonal steroid modulator primarily for the treatment of Duchenne Muscular Dystrophy ("DMD").

To date Actelion has paid a total of USD 10 million to ReveraGen which has been expensed as R&D costs. Under the terms of the agreement Actelion will also support R&D activities up to a maximum amount of USD 1 million p.a. for the next three years. In addition, Actelion acquired an option to obtain the exclusive worldwide license rights on vamorolone at any time but not later than following the receipt of the Phase IIb study results. If the option is exercised, ReveraGen will be entitled to receive up to USD 165 million in development and regulatory milestones for the DMD indication and up to USD 190 million for three further indications depending on achievement of certain development, regulatory approval and commercialization milestones. Furthermore, Actelion will pay increasing tiered single- to double-digit royalties on the net sales of vamorolone.

Actelion / Nippon Shinyaku alliance

Actelion and Nippon Shinyaku entered into an exclusive worldwide alliance in April 2008 to collaborate on selexipag, the first selective oral prostacyclin IP receptor agonist, for patients suffering from pulmonary arterial hypertension (PAH).

Selexipag was originally discovered and synthesized by Nippon Shinyaku and has major potential as a novel treatment of pulmonary arterial hypertension.

Actelion is responsible for global development and commercialization of selexipag outside Japan, while the two companies will co-develop and co-commercialize the drug in Japan.

Actelion / Bayer Schering Pharma AG alliance
Actelion holds the exclusive US rights for inhaled iloprost, marketed under the brand name Ventavis®, an inhaled treatment for pulmonary arterial hypertension (PAH), licensed from Bayer Schering Pharma AG (through the acquisition of CoTherix Inc.). Actelion has the US development responsibilities, and has established a joint Development and Commercialization Committee for future collaboration with Bayer Schering Pharma AG. Actelion books all sales of Ventavis® in the US, and pays a royalty on sales to Bayer Schering Pharma AG. In addition to this royalty, Actelion is contractually required to pay one final milestone payment to Bayer Schering Pharma AG upon achieving a set sales target.

Actelion / Oxford GlycoSciences alliance
In November 2002, Actelion in-licensed miglustat, the active ingredient of Zavesca®, from Oxford GlycoSciences (UK) Ltd. Zavesca came to the market in the European Union in March 2003, followed by the United States in January 2004. In November 2005, Actelion entered an agreement with UCB S.A., the legal successor to Oxford GlycoSciences under which UCB S.A. assigned all rights and obligations regarding miglustat, including worldwide marketing rights, to Actelion (except in Israel, the West Bank and the Gaza Strip).



Business Development
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
CH-4123 Allschwil
Phone: +41 61 565 63 16
Fax: +41 61 565 65 00
Contact us onlineHow to get to us

Key Account Manager, Sales and Marketing, Brazil 


"I enjoy working for Actelion because of its true commitment to Science in every detail."